MoonLake Immunotherapeutics (MLTX) News Today $36.77 +1.02 (+2.85%) Closing price 04:00 PM EasternExtended Trading$36.75 -0.02 (-0.05%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Fmr LLC Has $343.39 Million Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Fmr LLC increased its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 28.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,341,391 shares of the company'sApril 13 at 5:24 AM | marketbeat.comWellington Management Group LLP Sells 92,960 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Wellington Management Group LLP cut its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 48.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 99,098 shares of the company's stock after selling 92,9April 13 at 4:19 AM | marketbeat.comFederated Hermes Inc. Buys 149,724 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Federated Hermes Inc. increased its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 13.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,280,052 shares of the company's stock after acquiring an addiApril 9, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 1-Year Low - Here's What HappenedMoonLake Immunotherapeutics (NASDAQ:MLTX) Reaches New 1-Year Low - Should You Sell?April 9, 2025 | marketbeat.comFinepoint Capital LP Has $24.26 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Finepoint Capital LP lifted its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 15.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 447,935 shares of the company's stock afteApril 8, 2025 | marketbeat.comMoonLake Immunotherapeutics: A Buy At DipsApril 8, 2025 | seekingalpha.comAlliancebernstein L.P. Buys 24,464 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Alliancebernstein L.P. boosted its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 2.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,022,604 shares of the company's stock after purchasing an additional 2April 7, 2025 | marketbeat.comCinctive Capital Management LP Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Cinctive Capital Management LP purchased a new position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,576 shares of the coApril 6, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on Moonlake stockApril 5, 2025 | investing.comClearbridge Investments LLC Acquires 9,106 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Clearbridge Investments LLC raised its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 26.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 43,380 shares of the company's stock after acquiring an additional 9,106 shares duriApril 5, 2025 | marketbeat.comMoonLake Immunotherapeutics secures up to $500M in non-dilutive financingApril 3, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Reaches New 52-Week Low - Should You Sell?MoonLake Immunotherapeutics (NASDAQ:MLTX) Reaches New 52-Week Low - What's Next?April 3, 2025 | marketbeat.comMoonLake Immunotherapeutics Secures $500 Million Non-Dilutive Financing from Hercules CapitalApril 3, 2025 | gurufocus.comMoonLake Immunotherapeutics Secures $500M Financing for GrowthApril 3, 2025 | tipranks.comMoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical UpdatesApril 3, 2025 | globenewswire.comPictet Asset Management Holding SA Sells 10,219 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Pictet Asset Management Holding SA lessened its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 346,617April 3, 2025 | marketbeat.comBIT Capital GmbH Makes New $1.12 Million Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)BIT Capital GmbH acquired a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,748 shares of the company's stock, valuedMarch 28, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Buy" from AnalystsShares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommMarch 28, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 2.9% - Still a Buy?MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 2.9% Higher - Still a Buy?March 19, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Royal Bank of CanadaRoyal Bank of Canada initiated coverage on MoonLake Immunotherapeutics in a report on Tuesday. They set an "outperform" rating and a $67.00 price objective on the stock.March 19, 2025 | marketbeat.comRBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform RecommendationMarch 18, 2025 | msn.comMoonLake Immunotherapeutics initiated with an Outperform at RBC CapitalMarch 18, 2025 | markets.businessinsider.comRBC Capital Initiates a Buy Rating on MoonLake Immunotherapeutics (MLTX)March 18, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics Advances Clinical Trials in 2024March 15, 2025 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. lowered its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 18.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 178,501 shares of the comMarch 14, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Hits New 52-Week Low - What's Next?MoonLake Immunotherapeutics (NASDAQ:MLTX) Reaches New 1-Year Low - Time to Sell?March 11, 2025 | marketbeat.comCandriam S.C.A. Sells 11,524 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Candriam S.C.A. lessened its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 227,476 shares of the company's stock after selling 11,524 sharesMarch 8, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Buy" by BrokeragesMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has received an average rating of "Buy" from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation anMarch 3, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for MLTX Q1 Earnings?MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Research analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst R. Selvaraju now forecasts that the companyMarch 3, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for MLTX Q1 Earnings?MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Leerink Partnrs issued their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a report released on Thursday, February 27th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($0.82)March 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Decreased by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd cut its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 54.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,229 shares of the company'sMarch 2, 2025 | marketbeat.comBrokers Offer Predictions for MLTX Q2 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for MoonLake Immunotherapeutics in a research report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith expects that the company will post earniMarch 1, 2025 | marketbeat.comWedbush Has Negative Forecast for MLTX Q1 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at Wedbush lowered their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research report issued to clients and investors on Wednesday, February 26th. Wedbush analyst Y. Zhong now anticipMarch 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Cut to $73.00 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group reduced their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a research report on Thursday.February 28, 2025 | marketbeat.comMoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday.February 28, 2025 | marketbeat.comNeedham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00Needham & Company LLC increased their target price on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a "buy" rating in a report on Thursday.February 28, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Announces Quarterly Earnings ResultsMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.09).February 27, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on ThursdayMoonLake Immunotherapeutics (NASDAQ:MLTX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comMoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c)February 26, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics Reports Q4 EPS of -$0. ...February 26, 2025 | gurufocus.comMoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateFebruary 26, 2025 | investing.comMoonLake Immunotherapeutics Advances Clinical Trials with Promising Financial OutlookFebruary 26, 2025 | gurufocus.comMoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateFebruary 26, 2025 | globenewswire.comIs MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?February 25, 2025 | msn.comMoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to AnalystsFebruary 23, 2025 | insidermonkey.comMoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20, 2025 | insidermonkey.comMoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20, 2025 | msn.comRice Hall James & Associates LLC Has $6.02 Million Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Rice Hall James & Associates LLC boosted its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 47.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,133 shares of the company's stock after buying an additional 3February 18, 2025 | marketbeat.comCongress Asset Management Co. Buys 6,352 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Congress Asset Management Co. grew its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 9.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 72,993 shares of the company's stock after acquiring anFebruary 18, 2025 | marketbeat.comFMR LLC's Strategic Acquisition of MoonLake Immunotherapeutics SharesFebruary 12, 2025 | gurufocus.com Remove Ads Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Media Mentions By Week MLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼1.090.78▲Average Medical News Sentiment MLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼53▲MLTX Articles Average Week Remove Ads Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ASND News Today ROIV News Today LNTH News Today TGTX News Today RVMD News Today BBIO News Today LEGN News Today BPMC News Today SRPT News Today TLX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLTX Stock Free MLTX Stock Alerts